Skip to main content

The Globe and Mail

The curious lure of conservative earnings estimates

What we're looking for

Companies that have put out earnings per share guidance lower than the EPS consensus from sell-side analysts.

Earnings season is in full swing, and thanks mainly to the euro zone's growing debt crisis, expectations for earnings growth are low.

Story continues below advertisement

There is often a disparity between the expectations of analysts and those of the companies in question. Identifying stocks with more conservative estimates than the Street may be a good way to keep underperformers out of your portfolio.

More about today's screen

This screen comes courtesy of Bloomberg's Constantin Cosereanu. The criteria is as follows:

Companies must be based in Canada or the United States;

a market cap greater than $100-million (U.S.);

the company's EPS guidance for the current fiscal year is less than the consensus broker estimate.

What we found

Story continues below advertisement

The screen returned 11 Canadian stocks and dozens of U.S. ones. For reasons of space, we've chosen the first 11 U.S. stocks as they appeared on the list.

At time of writing, corporate earnings news in general has not been good. Only one of the 16 companies that have reported as of Wednesday night has beaten expectations. Three companies have reported results in line with expectations, and 12 companies have missed expectations.

With expectations of record or near-record second-quarter earnings, Potash Corp. is forecasting earnings for the full year to be in the range of $3.40 per share, 7 cents lower than the consensus broker estimate.

There is currently a multibillion U.S. antitrust lawsuit by potash buyers that accuses Potash Corp. and others of acting like a cartel.

Potash Corp. will announce its earnings on July 26.

Among U.S.-listed companies in our list, Big Pharma stalwart Pfizer is forecasting earnings for the full year of $2.19 per share, while the Street is expecting $2.21.

Story continues below advertisement

In an industry that has seen better days, Pfizer has had a particularly hard time. Its stock is underperforming peers like Merck and Abbott Labs. It faces several lawsuits for anticompetitive behaviour. And two of the world's largest emerging markets – India and China – are enacting policies that will make generic drugs very cheap or absolutely free, which will eat into Pfizer's bottom line.

Pfizer will announce its earnings on July 31.

Report an error Licensing Options
About the Author
Streetwise editor

Jody White is the web editor for Streetwise. He previously worked as a senior editor at Canadian Business Online and has written for MoneySense Magazine, Maclean's, the National Post and other national publications. More

Comments

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨